This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson-White, A. J. Articles by Stratakis, C. A. Search for Related Content PubMed PubMed Citation Articles by Robinson-White, A. J. Articles by Stratakis, C. A.

PRKAR1A Inactivation Leads to Increased Proliferation and Decreased Apoptosis in Human B Lymphocytes

¹ Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development and ² Dermatology Branch, National Cancer Institute, NIH, Bethesda, Maryland and ³ Mouse Cancer Genetics Program, National Cancer Institute, Frederick, Maryland

Requests for reprints: Constantine A. Stratakis, Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, NIH, Building 10, CRC, Room 1-3330, 10 Center Drive, MSC1103, Bethesda, MD 20892. Phone: 301-496-4686/6683; Fax: 301-402-0574/480-0378; E-mail: stratakc{at}mail.nih.gov.

The multiple neoplasia syndrome Carney complex (CNC) is caused by heterozygote mutations in the gene, which codes for the RI regulatory subunit (PRKAR1A) of protein kinase A. Inactivation of PRKAR1A and the additional loss of the normal allele lead to tumors in CNC patients and increased cyclic AMP signaling in their cells, but the oncogenetic mechanisms in affected tissues remain unknown. Previous studies suggested that PRKAR1A down-regulation may lead to increased mitogen-activated protein kinase (MAPK) signaling. Here, we show that, in lymphocytes with PRKAR1A-inactivating mutations, there is increased extracellular signal-regulated kinase (ERK) 1/2 and B-raf phosphorylation and MAPK/ERK kinase 1/2 and c-Myc activation, whereas c-Raf-1 is inhibited. These changes are accompanied by increased cell cycle rates and decreased apoptosis that result in an overall net gain in proliferation and survival. In conclusion, inactivation of PRKAR1A leads to widespread changes in molecular pathways that control cell cycle and apoptosis. This is the first study to show that human cells with partially inactivated RI levels have increased proliferation and survival, suggesting that loss of the normal allele in these cells is not necessary for these changes to occur. (Cancer Res 2006; 66(21): 10603-12)

This article has been cited by other articles:

				M. Q. Almeida, M. Muchow, S. Boikos, A. J. Bauer, K. J. Griffin, K. M. Tsang, C. Cheadle, T. Watkins, F. Wen, M. F. Starost, et al. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling Hum. Mol. Genet., January 27, 2010; (2010): ddq014v2 - ddq014. [Abstract] [Full Text] [PDF]

				X. Gao and T. B. Patel Regulation of Protein Kinase A Activity by p90 Ribosomal S6 Kinase 1 J. Biol. Chem., November 27, 2009; 284(48): 33070 - 33078. [Abstract] [Full Text] [PDF]

				A. J. Robinson-White, I. Bossis, H.-P. Hsiao, M. Nesterova, W. W. Leitner, and C. A. Stratakis 8-Cl-Adenosine Inhibits Proliferation and Causes Apoptosis in B-Lymphocytes via Protein Kinase A-Dependent and Independent Effects: Implications for Treatment of Carney Complex-Associated Tumors J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4061 - 4069. [Abstract] [Full Text] [PDF]

				J. Bertherat, A. Horvath, L. Groussin, S. Grabar, S. Boikos, L. Cazabat, R. Libe, F. Rene-Corail, S. Stergiopoulos, I. Bourdeau, et al. Mutations in Regulatory Subunit Type 1A of Cyclic Adenosine 5'-Monophosphate-Dependent Protein Kinase (PRKAR1A): Phenotype Analysis in 353 Patients and 80 Different Genotypes J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2085 - 2091. [Abstract] [Full Text] [PDF]

				E. Meoli, I. Bossis, L. Cazabat, M. Mavrakis, A. Horvath, S. Stergiopoulos, M. L. Shiferaw, G. Fumey, K. Perlemoine, M. Muchow, et al. Protein Kinase A Effects of an Expressed PRKAR1A Mutation Associated with Aggressive Tumors Cancer Res., May 1, 2008; 68(9): 3133 - 3141. [Abstract] [Full Text] [PDF]

				A. J. Robinson-White, H.-P. Hsiao, W. W. Leitner, E. Greene, A. Bauer, N. L. Krett, M. Nesterova, and C. A. Stratakis Protein Kinase A-Independent Inhibition of Proliferation and Induction of Apoptosis in Human Thyroid Cancer Cells by 8-Cl-Adenosine J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1020 - 1029. [Abstract] [Full Text] [PDF]

				M. Nesterova, I. Bossis, F. Wen, A. Horvath, L. Matyakhina, and C. A. Stratakis An Immortalized Human Cell Line Bearing a PRKAR1A-Inactivating Mutation: Effects of Overexpression of the Wild-Type Allele and Other Protein Kinase A Subunits J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 565 - 571. [Abstract] [Full Text] [PDF]

				A. Horvath, I. Bossis, C. Giatzakis, E. Levine, F. Weinberg, E. Meoli, A. Robinson-White, J. Siegel, P. Soni, L. Groussin, et al. Large Deletions of the PRKAR1A Gene in Carney Complex Clin. Cancer Res., January 15, 2008; 14(2): 388 - 395. [Abstract] [Full Text] [PDF]